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Regulatory T (Treg) cells expressing the transcription
factor forkhead box P3 (FoxP3) control immune re-
sponses and prevent autoimmunity. Treatment with
glucocorticoids (GCs) has been shown to increase
Treg cell frequency, but the mechanisms of their
action on Treg cell induction are largely unknown.
Here, we report that glucocorticoid-induced leucine
zipper (GILZ), a protein induced by GCs, promotes
Treg cell production. In mice, GILZ overexpression
causes an increase in Treg cell number, whereas
GILZ deficiency results in impaired generation of pe-
ripheral Treg cells (pTreg), associated with increased
spontaneous and experimental intestinal inflamma-
tion. Mechanistically, we found that GILZ is required
for GCs to cooperate with TGF-b in FoxP3 induction,
while it enhances TGF-b signaling by binding to and
promoting Smad2 phosphorylation and activation
of FoxP3 expression. Thus, our results establish an
essential GILZ-mediated link between the anti-
inflammatory action of GCs and the regulation of
TGF-b-dependent pTreg production.
INTRODUCTION
FoxP3+ regulatory T (Treg) cells restrain the immune responses
to self-antigens, pathogens, allergens, and commensal micro-
organisms (Feuerer et al., 2009; Josefowicz et al., 2012a). Treg
cells are produced in the thymus (tTreg) but may also be gener-
ated in the periphery (pTreg) or in vitro (iTreg) by conversion of
naive conventional T (Tconv) cells (Curotto de Lafaille and La-
faille, 2009; Yadav et al., 2013). Recent evidence suggests that
both tTreg and pTreg cells are collectively needed to establish
and maintain tolerance (Haribhai et al., 2011; Josefowicz et al.,
2012b; Samstein et al., 2012). Signals required for pTreg conver-
sion include transforming growth factor b (TGF-b), interleukin-2
(IL-2), and antigen presentation by dendritic cells. However,
additional factors in tissue microenvironment, such as retinoic
acid, microbiota, and its derivatives, contribute to the generation464 Cell Reports 7, 464–475, April 24, 2014 ª2014 The Authorsof pTreg (Atarashi et al., 2011; Coombes et al., 2007; Smith et al.,
2013; Sun et al., 2007). Thus, it is important to identify factors
that influence formation and maintenance of specific Treg
subsets.
TGF-b signaling is a requisite for the peripheral induction of
FoxP3 in naive T cells and generation of pTreg cells (Josefo-
wicz et al., 2012a; Yadav et al., 2013). TGF-b-mediated activa-
tion of TGF-b receptors leads to phosphorylation and nuclear
translocation of receptor-associated Smad proteins, leading
to target gene activation (Li and Flavell, 2008). During TGF-
b-mediated conversion of mature naive T cells, activated
Smad2 and Smad3 bind to foxp3 conserved enhancer region
(CNS1) and cooperate with NFATc in FoxP3 induction (Taki-
moto et al., 2010; Tone et al., 2008). Therefore, signaling events
and factors that promote or interfere with Smad phosphoryla-
tion and nuclear translocation are expected to affect Treg
differentiation.
Glucocorticoid (GC) hormones are produced in adrenal glands
in response to various types of stress, including inflammation
(Kadmiel and Cidlowski, 2013). As potent immunosuppressors,
synthetic GCs are widely used in clinics for the treatment of
various autoimmune and inflammatory conditions, including
inflammatory bowel diseases (IBDs) (Faubion et al., 2001). Inter-
estingly, both in humans and mice, treatment with dexametha-
sone (Dex) increases the frequency of Treg cells, suggesting
that GC-mediated immune suppression is in part achieved
through the gain of Treg cell number or activity (Chen et al.,
2006; Hu et al., 2012; Ling et al., 2007; Sua´rez et al., 2006).
The mechanisms of GC-mediated increase in Treg frequency
may involve differential sensitivity of Teff and Treg cells to GC-
induced cell death (Chen et al., 2004), or facilitated generation
of Treg cells upon GC stimulation (Barrat et al., 2002; Chung
et al., 2004; Prado et al., 2011). To this end, GCs synergize
with TGF-b signaling in FoxP3 induction (Karagiannidis et al.,
2004; Prado et al., 2011). However, factors that are mediating
the GC effect on FoxP3 expression and Treg cells have not
been identified.
Glucocorticoid-induced leucine zipper (GILZ) was initially
identified in thymocytes and peripheral T cells treated by Dex
(D’Adamio et al., 1997). It is a highly responsive and predictive
GC target shown to mediate several anti-inflammatory effects
of GCs, including suppression of cell growth and regulation of
cell differentiation (Ayroldi et al., 2001; Bruscoli et al., 2010, 2012;
Cannarile et al., 2006; Yosef et al., 2013).
Because GCs have been shown to induce Treg cells, and
because GILZ is a mediator of GC effects in several contexts,
we investigated the role of GILZ in Treg development and ho-
meostasis. We report that GILZ is involved in the production of
pTreg cells in vivo and that this function involves the regulation
of TGF-b signaling. Moreover, GILZ is required for GC-mediated
increase in Treg cells and FoxP3 expression. Thus, GILZ medi-
ates GC-induced Treg generation by promoting TGF-b signaling.
RESULTS
GILZ Controls the Number of Treg Cells in the Periphery
To investigate the role of GILZ in GC-mediated Treg induction, as
well as its physiological function in T cells, we generated mice
with T cell-specific deletion of the gilz gene (gilz conditional
knockout [cKO]) by breeding mice bearing the floxed gilz allele
with CD4-Cre transgenic mice. We confirmed the absence of
GILZ protein in thymocytes and in mature CD4+ T cells purified
from the spleens and peripheral and mesenteric lymph nodes
(pLNs and mLNs, respectively) of gilz cKO mice (Figure S1A).
Mice lacking GILZ in T cells showed normal frequencies and
the number of CD4CD8 double-negative, CD4+CD8+ dou-
ble-positive, and CD4+/CD8+ single-positive (SP) T cell subpop-
ulations in thymus and peripheral lymphoid organs (Figure S1B).
These data demonstrated that GILZ is dispensable for normal
T cell development and formation of CD4+ and CD8+ cells.
We next tested whether GILZ, as an effector of GCs, regulates
the production of Treg cells in vivo. gilz cKOmice showed similar
frequency and the absolute number of CD4+FoxP3+ tTreg cells
compared to their littermate controls (Figures 1A–1C). Because
tTreg cells were still formed in the absence of GILZ, we
concluded that GILZ was not essential for the development of
FoxP3+ cells in the thymus.
To the contrary, the frequency and the absolute number of
CD4+FoxP3+ cells found in spleens (Figures 1D and 1E) and
mLNs (Figures 1G and 1H) of 9- to 11-week-old mice were
moderately but significantly diminished in gilz cKO mice
compared to controls, despite similar total number of cells (Fig-
ures 1F and 1I), and CD4+ cells were present in the respective
organs (Figure S1B). GILZ-deficient mice also did not support
an age-dependent increase in the frequency of FoxP3+ cells
because a smaller proportion of CD4+ T cells expressed FoxP3
in the spleens of 12-month-old gilz cKO mice (Figure 1J).
As a complement to the gene deletion approach, we also ad-
dressed the effect of GILZ overexpression on Treg cell formation
in mice constitutively overexpressing GILZ in T cell lineage (gilz
TG) (Delfino et al., 2004). Forced expression ofGILZcausedan in-
crease in the frequency and the absolute number of CD4+FoxP3+
cells in spleens (Figures 1K and 1L) and mLNs (Figures 1M and
1N), without affecting the number of CD4 and CD8 SP cells (Fig-
ures S1C and S1D). Collectively, these data demonstrate that
GILZpositively regulates thenumberof Tregcells in theperiphery.
GILZ Is Required for pTreg Cell Formation
The decrease in Treg cell number was not associated with the
reduced capacity of GILZ-deficient cells to cycle in vivo (Fissonet al., 2003), as measured by the expression of the proliferation
marker Ki67 (Figure S2A). GILZ-deficient CD4+CD25+ cells also
did not reveal evidence of decreased survival because we
detected similar rates of spontaneous apoptosis in vitro (Fig-
ure S2B), caspase activity (Figure S2C), and the expression of
pro- and antiapoptotic genes of the bcl2 family (Figure S2D).
The Treg reduction could also not be ascribed to a reduced
production of TGF-b or IL-2 becauseGILZ-deficient CD4+CD25
cells produced similar levels of Tgfb1 and Il2mRNA (Figures S2E
and S2F). To further demonstrate that the decrease in the periph-
eral Treg cell number in gilz cKO mice was not due to their
reduced maintenance in vivo, we have intravenously (i.v.) in-
jected carboxyfluorescein succinimidyl ester (CFSE)-labeled
lymphocytes isolated from the spleens and pLNs of wild-type
(WT) and gilz cKO mice (CD45.2+ allotype) into unmanipulated
congenic hosts (CD45.1+ allotype) and followed the survival
and proliferation of donor-derived cells over time. The number
of gilz cKO CD45.2+CD4+FoxP3+ (Figure S2G, left) and
CD45.2+CD4+FoxP3 cells (Figure S2G, right) did not sig-
nificantly differ from that of donor-derived WT cells. This is in
agreement with a similar frequency of WT and gilz cKO
CD4+FoxP3+ cells that have divided in vivo, as detected by dilu-
tion of the CFSE dye (Figure S2H).
Normal tTreg frequencies and a relatively small decrease in
Treg cell number in the periphery point to the possibility that
GILZ regulates the generation of pTreg cells that constitute
less than 20% of peripheral Treg pool size in C57Bl/6 mice
(Weiss et al., 2012; Yadav et al., 2012). Naive GILZ-deficient
CD4+ T cells showed impaired induction of FoxP3 in vitro,
compared to similarly treated WT cells (Figure 2A). The defect
was specific to iTreg differentiation because naive gilz cKO
T cells efficiently upregulated the mRNA expression of Th1,
Th2, and Th17 master regulators under relative polarizing condi-
tions (Figure 2B). To test whether GILZ regulates pTreg cell
generation in vivo, we have evaluated conversion of naive
CD4+CD25CD45Rbhi T cells from WT and gilz cKO mice upon
transfer into RAG1/ mice. We found that about 2.5% of WT
Tconv cells isolated from the mLNs of recipient mice had differ-
entiated into FoxP3+ pTreg cells. In contrast, significantly fewer
GILZ-deficient T cells became FoxP3+ (Figure 2C). The differ-
ence in conversion between WT and GILZ-deficient cells was
stronger evidenced in colon lamina propria (LP) because less
than 1% (4-fold decrease) of CD4+ T cells isolated from colon
LP ofmice transferredwith GILZ-deficient Tconv cells expressed
FoxP3 (Figure 2D). These results demonstrate that Tconv cells
lacking GILZ were defective in converting into Treg cells both
in vitro and in vivo.
pTreg cells generated in a tolerogenic environment are largely
Nrp-1 (Weiss et al., 2012; Yadav et al., 2012).We thus have used
the expression of Nrp-1 to distinguish tTreg and pTreg cells and
to test whether the Treg decrease in gilz cKOmice derives from a
selective loss of pTreg cells. We have found that gilz cKO mice
have a significant decrease in the frequency (Figures 2E and
2F) and the number of CD4+FoxP3+Nrp-1 pTreg cells (Fig-
ures 2G and 2H, left), whereas the absolute number of
CD4+FoxP3+Nrp-1+ tTreg cells did not differ (Figures 2G and
2H, right). Consistent with the idea that GILZ regulates pTreg pro-
duction, the frequency and the number of CD4+FoxP3+ cellsCell Reports 7, 464–475, April 24, 2014 ª2014 The Authors 465
Figure 1. GILZ Controls the Number of Treg
Cells in the Periphery
(A) Flow cytometry analysis of CD4 and FoxP3
expression in thymi of 9- to 11-week-oldWT and gilz
cKO mice. N.S., not significant.
(B) Number of CD4+FoxP3+ cells in thymi of 9- to
11-week-old WT and gilz cKO mice.
(C) Number of cells in thymi of 9- to 11-week-oldWT
and gilz cKO mice (n = 10/group).
(D and E) Frequency (D) and number (E) of
CD4+FoxP3+ cells in spleens of 9- to 11-week-old
WT and gilz cKO mice.
(F) Number of cells in spleens of 8- to 12-week-old
WT and gilz cKO mice (n = 20/group).
(G and H) Frequency (G) and number (H) of
CD4+FoxP3+ cells in mLNs isolated from 8- to
11-week-old WT and gilz cKO mice.
(I) Number of cells in mLNs of 8- to 12-week-old WT
and gilz cKO mice (n = 10/group).
(J) Frequency of FoxP3+ cells among CD4+ cells in
spleens of 12-month-old WT and gilz cKO mice
(n = 5/group).
(K and L) Frequency (K) and number (L) of
CD4+FoxP3+ cells in spleens of 12- to 13-week-old
WT and gilz TG mice.
(M and N) Frequency (M) and number (N) of
CD4+FoxP3+ cells in mLNs of 12- to 13-week-old
WT and gilz TG mice.
Numbersclose to thegatesshowthe frequencyof the
gated population. Each symbol represents an indi-
vidualmouse; small horizontal lines indicate themean
(A–L). Graphs represent mean ± SEM. Data are from
one (M and N), or a pool of two (K and L), three (A–C
and G–H), or six (D–F) independent experiments.
See also Figure S1.were strongly downregulated in the colon of gilz cKO mice (Fig-
ures 2I–2K). Altogether, our data suggest that the absence of
GILZ selectively affects generation of pTreg cells in theperiphery.
Analysis of GILZ expression in CD4+CD25 and CD4+CD25+
purified from WT mice shows that both GILZ mRNA and protein
were found at higher levels in CD4+CD25 T cells than in
CD4+CD25+ Treg-enriched cells (Figures S3A and S3B). This
suggests that GILZ is required in Tconv cells for efficient Treg
conversion and suggests that it might be dispensable for the
Treg function, once they are formed. Consistent with this idea,466 Cell Reports 7, 464–475, April 24, 2014 ª2014 The Authorswe have not found differences in the
expression of Treg-associated markers
such as CD25, GITR, and CTLA-4, as well
as activation markers such as CD69 and
CD103 between WT and GILZ-deficient
CD4+FoxP3+ cells (Figure S3C). Because
the expression of FoxP3 closely correlated
with CD25 expression in gilz cKOmice as it
is observed in WT mice (data not shown),
we used CD25 expression to purify Treg
cells for functional studies. Cotransfer of
an equal number of WT and GILZ-deficient
CD4+CD25+ cells with naive colitogenic
WTCD4+CD25CD45Rbhi cells into immu-
nodeficient hosts (Powrie et al., 1993) revealed a similar capacity
of GILZ-deficient Treg cells to suppress effector cell expansion
and body weight loss caused by Tconv-mediated colitis to the
one of the WT CD4+CD25+ cells (Figures S3D and S3E). In
agreement with the unimpaired in vivo suppressor function of
GILZ-deficient Treg cells, we found similar amounts of transcript
and per-cell protein levels of FoxP3 (Figures S3F and S3G).
Taken together, these data suggest that GILZ is expressed
and is required in Tconv cells for pTreg conversion and is
dispensable in Treg suppressive function.
Figure 2. GILZ Is Required for pTreg Cell
Formation
(A) Quantitative real-time PCR analysis of
Foxp3 mRNA expression in sorted naive
CD4+CD62LhiCD44loCD25 T cells differentiated
for 48 hr in Th0 and iTreg conditions (as described
in the Experimental Procedures).
(B) Quantitative real-time PCR analysis of Tbx21,
Gata3, and RorcmRNA expression in naive T cells
differentiated for 48 hr in Th1, Th2, and Th17
conditions. Data in (A) and (B) are presented rela-
tive to the expression of Actb mRNA.
(C and D) Frequency of CD4+FoxP3+ cells in mLNs
(C) and LP (D) of Rag1/ mice at 6 weeks
following the adoptive transfer of CD4+CD25
CD45RBhi cells isolated from WT and gilz cKO
mice (n = 5–6/group).
(E and F) Flow cytometry analysis of Npr-1
expression on CD4+FoxP3+ cells in spleens (E)
and mLNs (F) of 11- to 20-week-old WT and gilz
cKO mice. Gray lines show fluorescence-minus-
one (FMO) controls for Nrp-1 staining.
(G and H) Number of FoxP3+Nrp-1 (left) and
FoxP3+Nrp-1+ (right) cells in spleens (G) andmLNs
(H) of WT and gilz cKO mice.
(I) Frequency of FoxP3+ cells among CD4+ cells in
colon LP of 10- to 12-week-old WT and gilz cKO
mice (n = 5/group).
(J and K) Frequency and number of CD4+FoxP3+
cells in colon LP of 12- to 20-week-old WT and gilz
cKO mice.
Graphs represent mean ± SEM. Data are repre-
sentative of three (A and B) or a pool of two (C and
D) or three (E–K) independent experiments.
See also Figure S2.Loss of Immune Homeostasis in Aged gilz cKO Mice
Deletion of GILZ did not result in general T cell activation and
overt inflammation (data not shown). Nevertheless, over time,
gilz cKO mice developed spontaneous colon inflammation, as
evidenced by a moderate increase in colonic LP lymphocytes
(Figure 3A) and colonweight-to-length ratio (Figure 3B) observed
in 12-month-old gilz cKO mice. This was associated with
the decrease in the frequency and the absolute number of
CD4+FoxP3+ cells in the colons of aged gilz cKOmice compared
to their WT controls (data not shown).
The infiltrating leukocytes produced more Ifng but not Il4 and
Il17mRNA (data not shown), whereas mLN cells (Figure 3C) andCell Reports 7, 464–4LP CD4+ T cells (Figure 3D) produced
more interferon (IFN)-g, but not IL-4
and IL-17 cytokines, suggesting that a
decrease in Treg cell number is associ-
ated with the loss of intestinal immune
homeostasis in aging gilz cKO mice.
Because in the gilz cKO mice, GILZ is
missing in all T cells, including Tconv
cells, we cannot exclude that the spon-
taneous colon inflammation develops
due to a self-intrinsic effect in Teff cells,
rather than to a reduced tolerance. CD4+FoxP3 Tconv and CD8+ cells isolated from 8- to 11-week-old
WT and gilz cKOmice showed similar activation and proliferation
states, as analyzed by the expression of CD62L, CD44, and Ki67
markers (Figures 3E and 3F). To directly address the effector
function of Tconv cells, we compared the ability of WT and
GILZ-deficient Tconv cells to induce colitis in vivo. Transfer of
naive CD4+CD25CD45Rbhi T cells sorted from gilz cKO mice
caused a similar degree of body weight loss and clinical signs
of colitis as the one causedby the transfer ofWTcells (Figure 3G).
Consistent with similar colitogenic activity, transferred WT and
GILZ-deficient CD4+FoxP3 T cells proliferated equally in the
mLNs of Rag1/ animals (Figure 3H) and were present at similar75, April 24, 2014 ª2014 The Authors 467
Figure 3. Loss of Immune Homeostasis in
Aged gilz cKO Mice
(A) Total number of lymphocytes isolated from colon
LP of 12-month-old WT and gilz cKO mice (n = 11/
group).
(B) Weight-to-length ratio of the colons of 12-
month-old WT and gilz cKO mice (n = 7–18/group).
(C) ELISA of IFN-g, IL-4, and IL-17 expression in
mLNs of aged (>12 months old) WT and gilz cKO
mice (n = 6–8/group).
(D) Intracellular flow cytometry analysis of IFN-g and
IL-17 expression by CD4+ cells isolated from colon
LP of aged WT and gilz cKO mice (n = 4/group).
(E) Flow cytometry analysis of CD62L and CD44 in
CD4+FoxP3 cells in spleens of 9- to 11-week-old
WT and gilz cKO mice (n = 8/group).
(F) Frequency of Ki67+ cells among CD4+FoxP3
and CD8+ cells in spleens of 9- to 11-week-old WT
and gilz cKO mice.
(G) Change in body weight of Rag1/ mice that
received WT or gilz cKO CD4+CD25CD45RBhi
cells, compared to control mice injected with PBS
(mean ± SD; n = 10/group).
(H) Frequency of Ki67+ cells among CD4+FoxP3
cells in mLNs of Rag1/ mice injected as in (F),
isolated 6 weeks after cell transfer (n = 4–6/group).
(I) Flow cytometry analysis of the IFN-g and IL-17
expression by mLNs isolated from Rag1/ mice
injected as in (G), 6 weeks after cell transfer. Plots
are representative of four to five mice per group.
(J) Change in bodyweight of Rag1/mice following
the adoptive transfer of CD4+CD25CD45RBhi from
WT (left) or gilz cKO (right) donors transferred alone
or together with CD4+CD25+ T cells sorted fromWT
donors (n = 7–9/group).
Graphs represent mean ± SEM. Data are from one
(J), two (C, D, and I), or a pool of three (A–H) or six
(E, left) experiments. See also Figure S3.numbers in the spleen and mLN (data not shown). Importantly,
GILZ-deficient Teff cells did not produce more IFN-g and IL-17
cytokines compared to WT cells (Figure 3I). Finally, the colito-
genic WT and gilz cKO cells were equally responsive to Treg-
mediated suppression because cotransfer of WT CD4+CD25+
cells significantly reversed the body weight loss caused by
both WT and gilz cKO CD4+CD25CD45Rbhi cells (Figure 3J).
Taken together, these data indicate that GILZ deficiency affects468 Cell Reports 7, 464–475, April 24, 2014 ª2014 The AuthorsTreg development and consistently leads
to Th1-type spontaneous tissue inflamma-
tion with age.
Lack of GILZ in T Cells Exacerbates
Chemically Induced Colitis
Because deregulated Teff and Treg cell
responses are implicated in the pathogen-
esis of IBD, and because aging gilz cKO
mice appear to be predisposed to the
development of colitis, we tested whether
GILZ deficiency influences the suscepti-
bility to experimentally induced colitis
(Cannarile et al., 2009). The severity of dini-trobenzene sulfonic acid (DNBS)-induced colitis, as measured
by body weight loss, diarrhea scoring, and colon shortening,
was markedly increased in gilz cKO mice compared to similarly
treated WT controls (Figures 4A–4C). The calculated colon
weight-to-length ratio, histologic damage, and total clinical
score were elevated in DNBS-treated gilz cKO mice, compared
to WT mice (Figures 4D–4F). An augmented degree of intestinal
inflammation was also evidenced by the increased levels of Tnfa
Figure 4. Lack of GILZ in T Cells Exacerbates
Chemically Induced Colitis
(A) Changes in body weight of WT and gilz cKOmice
during the course of DNBS-induced colitis. Mice
were put on a diet on day 1, and DNBS was
administered at Day 0.
(B) Diarrhea score of WT and gilz cKO mice at 3
consecutive days following DNBS administration
(mean ± SD; n = 12–13/group).
(C) Colon length of WT and gilz cKO mice at day 3
after DNBS administration.
(D) Ratio between colon weight and colon length in
WT and gilz cKO mice with DNBS-induced colitis.
(E) Histology of the colon in control and DNBS-
treatedWT and gilz cKOmice. Arrows indicate signs
of morphological damage and/or leukocytes infil-
tration.
(F) Total colitis score in WT and gilz cKO mice with
DNBS-induced colitis at day 3 after DNBS admin-
istration (n = 7–8/group).
(G) Quantitative real-time PCR analysis of Tnfa
mRNA expression in mLN cells (left) and in colon
LP lymphocytes (right), presented relative to the
expression of Actb mRNA (n = 7–8/group).
(H) ELISA of INF-g (left) and IL-17 (right) in super-
natants of lymphocytes isolated from colon LP of
WT and gilz cKO mice at day 3 after DNBS admin-
istration and cultured with plate bound anti-CD3
and anti-CD28 Abs for 48 hr (n = 3/group).
(I) Quantitative real-time PCR analysis of Tgfb1
expression in mLNs and in LP, presented relative to
the expression of Actb mRNA (n = 7–8/group).
(J) Number of FoxP3+CD4+ cells in mLNs isolated
from WT and gilz cKO mice at day 3 after DNBS
administration (n = 4/group).
(K and L) Changes in body weight (K) and diarrhea
score (L) of WT and gilz cKO mice during the course
of DNBS-induced colitis with or without pretransfer
of WT CD4+CD25+ cells (Treg).
(M) Colon length of WT and gilz cKO mice at day 3
after DNBS administration, with or without Treg
transfer.
Graphs represent mean ± SEM. Data are pooled
from two (G and I–M) or five (A–F) experiments or
from one of two experiments with similar results (H).
See also Figure S4.transcripts in mLNs and the colon LP of DNBS-treated gilz cKO
mice, compared to similarly treated WT controls (Figure 4G). Of
note, we did not detect elevated production of IL-17 and IFN-g
by lymphocytes isolated from the colon LP of DNBS-treated
gilz cKO mice (Figure 4H). Lower expression of Tgfb1 mRNA in
mLNs and LP pointed to attenuated suppressive responses in
GILZ-deficient mice (Figure 4I). Consistently, we have found a
reduced frequency of FoxP3+ cells in mLNs of gilz cKOmice dur-
ing the first 3 days of colitis (Figure 4J), whereas the frequency of
FoxP3IL-10+ cells and overall production of IL-10 did not seem
to vary (data not shown). Importantly, the pretransfer of WT Treg
cells reversed the increased susceptibility to DNBS into gilz cKO
mice (Figures 4K–4M).Moreover, we have also observed that gilz
cKO mice are more susceptible to oxazolone-induced colitis
(Th2 type), suggesting that pTreg deficiency observed in thesemicemay also favor Th2-type intestinal inflammation (Figure S4).
Taken together, these results demonstrate that gilz cKO mice
develop stronger intestinal inflammation in response to chemi-
cally induced tissue damage, a phenotype associated with
reduced Treg cell number.
GILZ Deficiency Precludes Dex-Mediated Alleviation of
DNBS-Induced Colitis, Induction of Treg Cells, and
Cooperation with TGF-b in FoxP3 Induction
GC treatment is extensively used in IBD therapy. We tested for
GILZ’s requirement for the responsiveness of DNBS-treated
mice to Dex treatment. Figure 5 shows that three daily injections
with Dex (1.5 mg/kg) accelerated the body weight recovery and
improved diarrhea score and overall clinical and histologic
score in DNBS-treated WT mice. Because one of the manyCell Reports 7, 464–475, April 24, 2014 ª2014 The Authors 469
Figure 5. GILZ Deficiency Precludes Dex-
Mediated Alleviation of DNBS-Induced Coli-
tis, Induction of Treg Cells, and Cooperation
with TGF-b in FoxP3 Induction
(A) Percentage of body weight of WT and gilz cKO
mice at day 3 after DNBS administration at day
0 and daily i.p. treatment with Dex (1.5 mg/kg)
relative to initial body weight. Control mice were
treated with PBS.
(B) Diarrhea score of WT and gilz cKO mice treated
as in (A).
(C) Total clinical score in WT and gilz cKO mice
treated as in (A) (n = 12–13/group).
(D) H&E-stained histologic slides from distal colon
sections (103) of WT and gilz cKOmice treated as in
(A). Arrows indicate signs of morphological damage
and/or leukocytes infiltration.
(E) Ratio between Treg and Tconv cell frequencies in
colons of WT and gilz cKOmice treated as in (A) (n =
3–5/group).
(F) Frequency of CD4+FoxP3+ cells in spleens iso-
lated from WT and gilz cKO mice treated for 3
consecutive days with Dex (1 mg/kg) (n = 3–5/
group).
(G)WB analysis of FoxP3 expression in CD4+CD25
cells isolated fromWT and gilz cKOmice, pretreated
with Dex (108M) for 24 hr in the presence of plate
bound anti-CD3 and anti-CD28 Abs and then
cultured for 48 hr in Th0 and iTreg conditions. Same
number of cells was loaded; WB with anti-Laminin-
B1 antibodies served as loading control. Graph
to the right shows densitometry analysis of FoxP3
expression.
Graphs represent mean ± SEM. Data are a pool of
five (A–C) or two (G) experiments, or from one of
three independent experiments with similar results
(E and F). See also Figure S5.anti-inflammatory effects of GCs is the increase of the Treg cell
frequency, we have analyzed and found the increase in the
Treg-to-Tconv cell ratio in the colons of WT mice (Figure 5E),
suggesting that modulation of Treg cell number in colon LP
contributes to the therapeutic effects of Dex. Of note, Dex treat-
ment did not change the Treg/Tconv ratio in gilz cKO mice, did
not promote body weight recovery, and did not alleviate the
colitis scores (Figures 5A–5E), thus showing that a lack of GILZ
precludes GC-mediated anti-inflammatory effects during colitis
treatment, which is associated with a GILZ-dependent increase
of Treg-to-Teff cell ratio.
We next tested whether GCs require GILZ to increase the
Treg cell frequency also in unmanipulated mice (Chen et al.,
2004). As expected, injection with Dex for 3 consecutive days
augmented the frequency of splenic CD4+FoxP3+ cells in 6- to
8-week-old WT mice (that at this age are not yet revealing sig-
nificant differences in Treg cell number), but it failed to do so in
mice lacking GILZ (Figure 5F). These results demonstrate that
GILZ is at least partially responsible for the GC-mediated effect
on Treg cells.470 Cell Reports 7, 464–475, April 24, 2014 ª2014 The AuthorsWe then tested whether GCs were able
to augment TGF-b-induced FoxP3 expres-
sion in the absence of GILZ (Prado et al.,2011). CD4+CD25 T cells purified from WT and gilz cKO mice
were activated for 24 hr in the presence of 108M Dex and
then stimulated with TGF-b to induce iTreg cell differentiation.
Pretreatment with Dex strongly increased the TGF-b-induced
FoxP3 expression in WT, but not in GILZ-deficient, cells (Fig-
ure 5G). Thus, GCs cooperate with TGF-b in FoxP3 induction
and Treg differentiation in a GILZ-dependent manner.
Because phosphorylated Smad proteins are critical effectors
of TGF-b signaling in T cells, we next tested whether Dex
enhanced the TGF-b-induced phosphorylation of Smad2
(p-Smad2). Figure S5A (top panel) shows that Dex resulted in
about a 2-fold increase in p-Smad2-to-total Smad2 protein level
ratio. Dex treatment alone did not significantly induce p-Smad2,
suggesting that Dex synergizes with TGF-b to induce p-Smad2
and FoxP3 expression. This idea is further supported by the
fact that the activity of TGF-b receptor I (TGF-bRI) was required
for the effect of Dex because Dex-pretreated cells that were also
treated with the selective inhibitor of TGF-bRI (SB 431542) were
not able to upregulate p-Smad2 (Figure S5B, top panel) and,
consequently, foxp3 mRNA (Figure S5C), upon stimulation with
TGF-b. Similar data were obtained using another TGF-bRI inhib-
itor, GW788388 (data not shown). We therefore conclude that
Dex synergizes with TGF-b in FoxP3 expression, and
the synergy involves modulation of GILZ expression and
p-Smad2.
GILZ Enhances TGF-b Signaling and FoxP3 Expression
via Direct Stimulation of TGF-b Signaling
To dissect the mechanism of GILZ’s effect on TGF-b signaling,
we tested the levels of p-Smad2 in WT and GILZ-deficient
CD4+CD25 T cells treated in vitro with TGF-b. GILZ-deficient
cells showed comparable levels of total Smad2 protein as WT
cells but reduced TGF-b-induced p-Smad2 (Figure 6A), suggest-
ing that TGF-b-induced signaling cascade is defective in T cells
lacking GILZ.
To test whether GILZ interacts with TGF-b downstream
signaling components, we first performed transient overexpres-
sion coimmunoprecipitation experiments in 293T cells. The
results show that GILZ interacts with Flag-tagged Smad2 and
Smad4 (Figures 6B and 6C), but not with Smad3 (Figure S6).
The binding between Smad proteins and GILZ is direct as shown
in glutathione S-transferase (GST) pull-down experiments using
GST-Tat-GILZ and Flag-Smad2/Smad4 purified from bacterial
extracts (Figure 6D). Importantly, we show that the interaction
between GILZ and Smad2 occurs physiologically in native
CD4+CD25 T cells upon stimulation with TGF-b (Figure 6E).
Smad2 and Smad3 are collectively essential for the activation
of the FoxP3 expression during iTreg cell conversion via their
direct binding to a foxp3 CNS1 (Takimoto et al., 2010; Tone
et al., 2008). To test whether the attenuated Smad phos-
phorylation observed in GILZ-deficient T cells results in their
compromised transcriptional activity, we performed chromatin
immunoprecipitation (ChIP) assays using CD4+CD25 T cells
purified from WT and gilz cKO mice and activated in vitro in the
presence of TGF-b. TGF-b induced Smad2 binding toCNS1 (Fig-
ure 6F, left) and consequent acetylation of histone H3 (Figure 6F,
right) only in GILZ-sufficient cells. Consistently, levels of FoxP3
protein expression, which was subsequently induced in WT
cells, were greatly reduced in cells lacking GILZ (Figure 6G).
Importantly, we were able to restore the foxp3mRNA expression
in GILZ-deficient CD4+CD25 cells, transfected with Smad2
expression vector and stimulated with TGF-b, to the levels
comparable to similarly treated WT cells (Figure 6H). Altogether,
these data demonstrate that GILZ interacts with Smad proteins
and ensures the efficient TGF-b-induced transcriptional cascade
for the expression of the Treg master regulator FoxP3.
DISCUSSION
FoxP3+ Treg cells are central in the control of immune and
inflammatory processes. Because GCs have been shown to
increase the expression of FoxP3 and the abundance of Treg
cells, we addressed the possible role of GC effector GILZ in
the development and function of FoxP3+ Treg cells and its
requirement for the GC effects on Treg cell frequency.
We have found that genetic ablation of GILZ in T cells results in
a reduced number of CD4+FoxP3+ cells in the spleens, mLNs,
and colon LP without affecting the number and function ofmature CD4+ and CD8+ cells. GILZ deficiency also did not affect
the number of Treg cells in the thymus, suggesting that GILZ is
dispensable for the tTreg cell development. This is consistent
with the notion that the TGF-b axis is mainly required for gener-
ation of pTreg but not of tTreg cells (Pesu et al., 2008; Samstein
et al., 2012; Schlenner et al., 2012; Takimoto et al., 2010; Zheng
et al., 2010).
Recent advances have allowed the use of Nrp-1 expression to
distinguish Treg cells produced in the thymus (FoxP3+Nrp-1+)
from peripherally derived pTreg cells (FoxP3+Nrp-1), generated
by conversion of mature CD4+ Tconv cells (Weiss et al., 2012;
Yadav et al., 2012) under steady-state conditions. The frequency
and number of FoxP3+Nrp-1 pTreg cells were reduced about
50% in the spleens and 70% in mLNs of gilz cKO mice, whereas
the number of FoxP3+Nrp-1+ tTreg cells was unaltered, consis-
tent with normal tTreg and defective pTreg cell formation.
Indeed, the decrease in Treg cell frequency and number be-
comes striking in in vivo conversion experiments, strongly
evidencing the defect in pTreg induction in the absence of
GILZ. Lack of difference in Treg number in newborn and 3- to
8-week-old mice (data not shown) is consistent with the differ-
ences appearing with the onset of pTreg development (Yadav
et al., 2012). Accordingly, the decrease in Treg cells was more
evident in colon LP, a site known to support pTreg cell genera-
tion (Curotto de Lafaille and Lafaille, 2009; Yadav et al., 2013).
Similarly, abrogation of Smad binding to CNS1 in mice affected
the induction of pTreg cells at mucosal sites without affecting the
number of Treg cells in the thymus (Josefowicz et al., 2012b;
Schlenner et al., 2012; Weiss et al., 2012; Zheng et al., 2010).
The fact that the pTreg production was not completely abro-
gated in gilz cKO mice suggests that other factors collaborate
with GILZ in Treg cell generation. Taken together, our data
demonstrate that the absence of GILZ affects the number of
extrathymically generated Treg cells in several settings: number
of spontaneously generated pTreg cells, through conversion
in vivo from Tconv cells, and in vitro, using TGF-b.
Expression pattern of GILZ in Tconv and Treg cells supports
the hypothesis that GILZ is required in naive T cells that undergo
Treg differentiation in the periphery because GILZ protein is
mostly detectable in CD4+CD25 cells and not in CD4+CD25+
Treg-enriched cells. Consistently, GILZ seems to regulate the
production of Treg cells and not their suppressive activity
because the fewer Treg cells that are nonetheless formed
without GILZ are equally potent in the suppression of T cell
activation as addressed in an experimental colitis model, sug-
gesting that GILZ is dispensable for Treg suppressive function.
Similarly, collective ablation of Smad2/Smad3 or CNS1 de-
creases pTreg cell conversion in vivo without negatively
affecting their function and maintenance (Gu et al., 2012; Jose-
fowicz et al., 2012b).
Consistent with the lack of tTreg defect and unaltered sup-
pressive function, gilz cKOmice did not display systemic autoim-
munity or premature mortality associated with general Treg cell
deletion (Josefowicz et al., 2012b; Kim et al., 2007). However,
they develop intestinal inflammation over time, associated with
an increase in IFN-g production. Therefore, we demonstrate
that, in addition to the described role of pTreg cells in the regu-
lation of Th2-type responses at mucosal body surfacesCell Reports 7, 464–475, April 24, 2014 ª2014 The Authors 471
Figure 6. GILZ Enhances TGF-b Signaling and FoxP3 Expression via Direct Stimulation of TGF-b Signaling
(A) WB analysis of p-Smad2 and Smad2 in WT and gilz cKO CD4+CD25 cells unstimulated or stimulated for 30 min with TGF-b in the presence of plate bound
anti-CD3 and anti-CD28 Abs. Graph to the right shows densitometry analysis of the p-Smad2-to-total Smad2 ratio.
(B and C) GILZ interacts with Smad2 and Smad4 proteins in vivo. 293T cells were cotransfected with GILZ and FLAG-tagged Smad2 (B) or Smad4 (C).
Immunoprecipitations (IP) were done with anti-Flag agarose beads, and the presence of GILZ (top panel) and Smads (second panel from the top) in immuno-
precipitates was evaluated by WB with antibodies against GILZ, or Flag.
(D) IP-WB analysis of the direct binding between Flag-Smad2, Flag-Smad4 and GST-Tat-GILZ purified from bacterial extracts.
(E) GILZ-Smad2 interaction in native T cells. Immunofluorescence images of in situ PLA performed on CD4+CD25 T cells isolated fromWT and gilz cKOmice and
activated in vitro for 30 min with plate bound anti-CD3 and anti-CD28 Abs, without (left panels) or with 5 ng/ml TGF-b (right panels). PLA was performed using
GILZ/Smad2 antibody mix. A representative merge of the red (PLA) and blue (DAPI) channel images is shown for each sample. Scale bar, 50 mm.
(F) ChIP assay of Smad2 binding and histone acetylation at the foxp3 CNS1 in WT and gilz cKO splenic CD4+CD25 T cells stimulated for 30 min (for Smad2) and
24 hr (for AcH3) as in (A). Cell lysates were immunoprecipitated with anti-Smad2 (left), anti-acetyl histone 3 (AcH3), or control IgG, and the presence of specific
regions in the immunoprecipitates was determined by quantitative real-time PCR.
(G) WB analysis of FoxP3 expression in WT and gilz cKO splenic CD4+CD25 cells stimulated for 48 hr as in (A). An equal number of cells was loaded, and b-actin
protein expression was used as a loading control.
(H) Expression of foxp3 mRNA in WT and gilz cKO CD4+CD25 T cells stimulated as in (A) for 24 hr, following the cell nucleofection with Smad2-expressing or
control vectors.
Graphs represent mean ± SEM of data pooled from two (F and H) or three (A) experiments. See also Figure S6.(Josefowicz et al., 2012b), the reduction of pTreg cells in gilz
cKOmice results in an increased susceptibility to Th1-type intes-
tinal inflammation.472 Cell Reports 7, 464–475, April 24, 2014 ª2014 The AuthorsTreg cells are critical in controlling intestinal immune homeo-
stasis. In colon, ablation of Treg cells leads to lethal intestinal
inflammation during experimentally induced colitis (Boehm
et al., 2012), whereas Treg reduction is observed in IBD (Eastaff-
Leung et al., 2010). pTreg cells are generated and abundant in
colon LP and are essential to control colitis. Importantly, treat-
ment with Treg cells resolved the colitis in an adoptive transfer
model, but only when pTreg cells were also present, further
stressing the potential distinct specialized function for pTreg
cells (Haribhai et al., 2009). An increase of colonic Treg cell
number induced by microbiota and its derivatives was shown
to correlate with suppression of the disease symptoms in an
experimental colitis model (Atarashi et al., 2011; Smith et al.,
2013). Consistently, mice with GILZ overexpression in T cells
show resistance to chemically induced colitis (Cannarile et al.,
2009; Delfino et al., 2004). Our data show that thesemice contain
numerically more Treg cells in the periphery, which could
improve immune tolerance in thesemice. Accordingly, a numeric
decrease in pTreg cells in gilz cKO mice is associated with an
increased susceptibility to DNBS-induced Th1-type colitis, a
phenotype that is reverted by the transfer of Treg cells. There-
fore, the colitis susceptibility correlates with the Treg cell number
changes, and not with the enhanced production of IFN-g, IL-4,
and IL-17 cytokines. Although the effect of GILZ deficiency on
Teff cell function cannot be excluded, as suggested by Th1
skewing, our data suggest that the numeric reduction in pTreg
cells in the absence of apparent functional differences in Teff
cells results in an increased susceptibility to colitis. Such results
have potential clinical implications because monitoring and
restoring adequate Treg levels may be exploited to cure IBD
and other autoimmune diseases.
Notably, gilz cKOmice were resistant to the therapeutic action
of GCs, which reduced the clinical features of colitis, such body
weight loss, diarrhea, and colon shortening in mice only if GILZ
was present. GC treatment led to the increase in the Treg/Teff
ratio in WT but not in GILZ-deficient mice. Both in mice with
ongoing colitis and in unmanipulated mice, the frequency of
CD4+FoxP3+ cells increases upon treatment with Dex depen-
dent on GILZ, thus demonstrating that GILZ mediates the events
triggered by Dex in T cells that lead to an increase in Treg
number. Importantly, we demonstrated that GCs promoted
TGF-b-induced FoxP3 expression in GILZ-sufficient but not in
GILZ-deficient cells, suggesting that GC and TGF-b cooperation
requires the action of GILZ.
We found that GILZ regulates TGF-b signaling. Duration and
strength of TGF-b signaling depend on Smad transcriptional
activity, which can be regulated at multiple levels, including
TGF-b receptor activity, interactions with nuclear binding part-
ners, and nuclear phosphatase activity (Li and Flavell, 2008). It
has been shown that both Smad2 and Smad3 contribute to
TGF-b-mediated foxp3 induction (Nolting et al., 2009; Takimoto
et al., 2010; Tone et al., 2008; Xu et al., 2010). Interestingly, GILZ
interacts with both Smad2 (receptor activated) and Smad4
(cytoplasmic/nuclear), but not Smad3. Importantly, interaction
of the endogenous GILZ and Smad2 was detected also in
TGF-b-stimulated native T cells. In the absence of GILZ,
TGF-b-dependent p-Smad2 is reduced, so as its consequent
binding to the CNS1 region and expression of FoxP3. Similar
to retinoic acid, GCs may facilitate the access of transcription
factors such as Smads to foxp3 locus via induction of GILZ (Nolt-
ing et al., 2009; Xu et al., 2010).Therefore, in addition to retinoic acid, microbiota, and its
metabolites (Atarashi et al., 2011; Coombes et al., 2007; Smith
et al., 2013; Sun et al., 2007), GILZ appears to contribute to
the TGF-b-mediated generation of the pTreg cells and control
intestinal homeostasis. Interestingly, colonic epithelial cells pro-
duce GCs locally at steady state and during inflammation (Cima
et al., 2004). Thus, strategies involving modulation of GILZ
expression might prove useful to enhance peripheral tolerance.
Altogether, these data establish GILZ as a modulator of Treg
cell homeostasis and suggest a physiologic crosstalk between
TGF-b signaling and stress hormones. Our study suggests that
the loss of pTreg cells in disease can be controlled with GCs
or with novel strategies involving GILZ. Besides clinical aspects,
our work opens new perspectives for the potential role of stress
hormones in physiologic modulation of Treg-controlled pro-
cesses including suppression of protective and damaging
immune responses.
EXPERIMENTAL PROCEDURES
Mice
Mice bearing a floxed gilz allele were generated and maintained on a C57Bl/6
background as described (Bruscoli et al., 2012). CD4-Cre transgenic and
Rag1/ mice were purchased from Jackson Laboratory; CD45.1 mice were
purchased from Charles River Laboratories. All procedures were approved
by the Ethical Committee of the University of Perugia.
Antibodies and Flow Cytometry
For the list of monoclonal antibodies (mAbs) used for flow cytometry analyses,
cell sorting, and in vitro assays, see Supplemental Experimental Procedures.
Staining for FoxP3 was performed using the FoxP3/Transcription Factor
Staining Buffer Set (eBioscience). Analysis and cell sorting were done using
a one- and two-laser standard configuration FACSCanto and FACSAria II
(BD Biosciences); data were analyzed using FlowJo software (TreeStar).
Adoptive Transfer of Colitis
CD4+CD25+ and naive CD4+CD25CD45Rbhi T cells were purified from
spleens by cell sorting (purity routinely exceeded 98%). A total of 400,000
CD4+CD25CD45Rbhi T cells alone or along with 125,000 CD4+CD25+
T cells were injected intraperitoneally (i.p.) into Rag1/mice. Clinical evidence
of disease and body weight were monitored weekly.
Induction of Colitis with DNBS
Mice were anesthetized with sodium thiopental (30 mg/kg) and xylazine
(10 mg/kg). A total of 3 mg of DNBS or 50% ethanol (2,4-dinitrobenzenesul-
fonic acid; Sigma-Aldrich) was administered per rectum. Body weight, stool
consistency, and rectal bleeding were examined daily, and total clinical score
was calculated as in Cannarile et al. (2009). For Treg transfer experiments, 33
106 CD4+CD25+ cells purified by magnetic sorting from spleens and mLNs of
WT mice were injected i.v. into WT or gilz cKO mice 1 day before DNBS
administration.
In Vivo Treatment with Dex
Mice were i.p. injected with 1.5 mg/kg of Dex or PBS and then were adminis-
tered with DNBS. Dex was also injected i.p. at day 1 and day 2 after DNBS
administration. For studies of the Dex effect on Treg cells without induction
of colitis, mice were i.p. injected with 1 mg/kg of Dex or PBS for 3 consecutive
days.
Histology
Tissues were fixed overnight in 10% formalin solution (Sigma-Aldrich), dehy-
drated in graded ethanol, embedded in paraffin (Sigma-Aldrich), and
sectioned. Sections were stained with hematoxylin and eosin (H&E) andCell Reports 7, 464–475, April 24, 2014 ª2014 The Authors 473
observed under an Olympus BX51 microscope equipped with a Leica EC3
camera.
Protein Interaction Assays and Immunoblotting
Protein extracts were obtained using RIPA buffer supplemented with protease
(Sigma-Aldrich) and phosphatase (Thermo Scientific) inhibitor cocktails.
Western blot (WB) analyses were performed with antibody against GILZ
(eBioscience), phospho-Smad2 (Cell Signaling Technology), Smad2 (Cell
Signaling Technology), FoxP3 (eBioscience), Laminin B1 (Abcam), b-actin
(Sigma-Aldrich), Flag (Sigma-Aldrich), and HA (Santa Cruz Biotechnology).
Coimmunoprecipitation studies were performed as described (Bereshchenko
et al., 2002) using pRKW2-Smad2-Flag, pRKW2-Smad4-Flag, pcDNA3.1(+)/
myc-HisB-GILZ, and pcDNA 3.1D/V5-His TOPO-Gilz-Flag expression vectors.
For the direct interaction assay, One Shot BL21(DE3)pLysS (Invitrogen) bacte-
ria were transformed with Smad2-Flag, Smad4-Flag, and GST-Tat-GILZ
expression vectors, and protein-protein interaction was assayed as described
by Bereshchenko et al., (2002).
In Situ Proximity Ligation Assay for Protein-Protein Interactions
Duolink proximity ligation assay (PLA) was performed according to the manu-
facturer’s instructions (Olink Bioscience; see also Supplemental Experimental
Procedures). Detection of the interaction signals was carried out by fluores-
cence microscopy using a Zeiss Axioplan fluorescence microscope equipped
with a Spot-2 cooled camera (Diagnostic Instruments).
ChIP Assay
ChIP assays were performed as described by Tone et al. (2008). In brief, cells
were fixed in 1% paraformaldehyde and sonicated on ice. Precleared lysates
were incubated overnight at 4C with polyclonal anti-Smad2 (Cell Signaling
Technology), anti-acetyl histone H3 (Millipore), or control rabbit IgG (Cell
Signaling Technology). Immunocomplexes were collected using the Chip
Assay Kit (Millipore), and quantitative real-time PCR analysis was performed
using the Power SYBR Green PCR Master Mix (Applied Biosystems) to deter-
mine the percentage of each analyzed region against input DNA. The quanti-
tative real-time PCR primers are listed in the Supplemental Information.
Statistical Analysis
Statistical analysis was performed with Prism 6.0 (GraphPad Software). The
nonparametric Mann-Whitney U test or a two-tailed unpaired Student’s t
test was used for statistical comparisons (*p < 0.05; **p < 0.005; ***p < 0.0005).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.03.004.
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